Abstract:Objectives Multiple warfarin pharmacogenetic algorithms have been published and been confirmed to predict warfarin dose more accurately than clinical algorithm or fixed-dose approach. However, their performance in Chinese patients has never been evaluated. We sought to compare the performance of published warfarin pharmacogenetic algorithms in a cohort of Chinese patients under warfarin anticoagulation. Methods The study population consisted of 282 unrelated Han-Chinese patients consecutively admitted to the General Hospital of Chinese People9s Liberation Army between January 2008 and July 2011. The patients had all undergone warfarin anticoagulation for various indications and were stably controlled with a target international normalisation ratio (INR) of 1.6–2.5. Genomic DNA extraction from each patient was followed by genotyping to detect the polymorphisms of CYP2C9*3 (rs1057910), VKORC1 −1639 G/A (rs9923231), and CYP4F2*3 (rs2108622) respectively, using standard techniques. A total of 8 eligible pharmacogenetic algorithms were selected for performance comparison. The performance of each algorithm was evaluated by calculating the percentage of patients whose predicted dose fell within 20% of their actual therapeutic dose (percentage within 20%), and the mean absolute error (MAE) between each predicted dose and actual stable dose. Results In the entire cohort, the pharmacogenetic algorithms could predict warfarin dose with the average MAE of 0.87±0.17 mg/day (0.73–1.17 mg/day), and the average percentage within 20% of 43.8%±8.1% (29.1–52.1%). By pair wise comparison, warfarin dose prediction was significantly more accurate with the algorithms derived from Asian patients (48.6–50.0%) than those from Caucasian patients (29.1–39.7%; OR 1.61–3.36, p≤0.02). Algorithms with additional covariates of INR values or CYP4F2*3 performed better than those without the covariates (adding INR: OR: 1.71 (1.08–2.72), p=0.029; adding CYP4F2*3: OR: 2.67 (1.41–5.05), p=0.004). When the patients were stratified according to the dose range, the algorithms from Caucasian and racially mixed populations tended to perform better in higher dose group (≥4.5 mg/day), and algorithms from Asian populations performed better in intermediate dose group (1.5–4.5 mg/day). None of the algorithms performed well in lower dose group (≤1.5 mg/day). Conclusions Our study indicated that none of the eligible pharmacogenetic algorithms could perform the best for all dosing ranges in the present cohort of Chinese patients under warfarin anticoagulation. It may be important to consider the ethnic and clinical specific characteristics when choosing the appropriate algorithm for a local service population. A more refinement pharmacogenetic algorithm combining 3 genotypes (CYP2C9, VKORC1 and CYP4F2) and clinical factors with INR response could potentially improve the warfarin dose prediction in Chinese patients.

A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials.

Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.

Comparative effectiveness of warfarin management strategies: a systematic review and network meta-analysis

Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.

Online Learning to Estimate Warfarin Dose with Contextual Linear Bandits

Genotype-guided Dosing Versus Conventional Dosing of Warfarin: A Meta-Analysis of 15 Randomized Controlled Trials.

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation

Web-Based Warfarin Management (Alfalfa App) Versus Traditional Warfarin Management: Multicenter Prospective Cohort Study

Efficacy and safety of genotype-guided warfarin dosing versus non-genotype-guided warfarin dosing strategies: A systematic review and meta-analysis of 27 randomized controlled trials

Estimation of the Warfarin Dose with A Pharmacogenetic Refinement Algorithm in Chinese Patients Mainly under Low-Intensity Warfarin Anticoagulation

Comparative Performance of Gene-Based Warfarin Dosing Algorithms in Chinese Patients

Development of A Novel Individualized Warfarin Dose Algorithm Based on A Population Pharmacokinetic Model with Improved Prediction Accuracy for Chinese Patients after Heart Valve Replacement

Warfarin- A Natural Anticoagulant: A Review of Research Trends for Precision Medication

Optimizing warfarin dosing for patients with atrial fibrillation using machine learning

New Internet-Based Warfarin Anticoagulation Management Approach After Mechanical Heart Valve Replacement: Prospective, Multicenter, Randomized Controlled Trial

Limited Clinical Utility of Genotype-Guided Warfarin Initiation Dosing Algorithms Versus Standard Therapy: a Meta-Analysis and Trial Sequential Analysis of 11 Randomized Controlled Trials

Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents